Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Serono/OSI's Novantrone Adds Boxed Warning On Leukemia And Cardiotoxicity

This article was originally published in The Pink Sheet Daily

Executive Summary

Serono and OSI added the warnings following cardiotoxicty reports from post-marketing surveillance and secondary acute myelogenous leukemia reports from peer-reviewed literature, spontaneous reports and a prospective observational study, a "Dear Doctor" letter states.

You may also be interested in...



Generic Mitoxantrone Launches For Oncology Indications

Serono still holds exclusivity for Novantrone’s multiple sclerosis indication.

Generic Mitoxantrone Launches For Oncology Indications

Serono still holds exclusivity for Novantrone’s multiple sclerosis indication.

Aventis Taxotere For Prostate Cancer Clears FDA With 2.5 Month Survival Benefit

Taxotere is the first drug to demonstrate a survival benefit in hormone refractory patients, FDA said. Aventis is investigating docetaxel as first-line therapy.

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel